Dienogest: an oral progestogen for the treatment of endometriosis

References

• Kennedy S, Bergqvist A, Chapron C et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum. Reprod.20, 2698–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Sinaii N, Plumb K, Cotton L et al. Differences in characteristics of 1,000 women with endometriosis based on extent of disease. Fertil. Steril.89, 538–545 (2008).
   PubMed Web of Science ®Google Scholar
• Ozkan S, Murk W, Arici A. Endometriosis-associated infertility. Ann. N. Y. Acad. Sci.1127, 92–100 (2008).
   PubMed Web of Science ®Google Scholar
• Mounsey AL, Wilgus A, Slawson DC. Diagnosis and management of endometriosis. Am. Fam. Physician74, 594–600 (2006).
   PubMed Web of Science ®Google Scholar
• Bischoff F, Simpson JL. Genetic basis of endometriosis. Ann. N. Y. Acad. Sci.1034, 284–299 (2004).
   PubMed Web of Science ®Google Scholar
• Missmer SA, Hankinson SE, Spiegelman D et al. Reproductive history and endometriosis among premenopausal women. Obstet. Gynecol.104, 965–974 (2004).
   PubMed Web of Science ®Google Scholar
• Aghajanova L, Velarde MC, Giudice LC. Altered gene expression profiling in endometrium: evidence for progesterone resistance. Semin. Reprod. Med.28, 51–58 (2010).
   PubMed Web of Science ®Google Scholar
• Guo SW. Epigenetics of endometriosis. Mol. Hum. Reprod.15, 587–607 (2009).
   PubMed Web of Science ®Google Scholar
• Tempfer CB, Simoni M, Destenaves B et al. Functional genetic polymorphisms and female reproductive disorders: part II – endometriosis. Hum. Reprod. Update15, 97–118 (2009).
   PubMedGoogle Scholar
• Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet. Gynecol. Clin. North Am.24, 235–258 (1997).
   PubMed Web of Science ®Google Scholar
• Wheeler JM. Epidemiology of endometriosis-associated infertility. J. Reprod. Med.34, 41–46 (1989).
   PubMed Web of Science ®Google Scholar
• Farquhar CM. Extracts from the ‘clinical evidence’. Endometriosis. Br. Med. J.320, 1449–1452 (2000).
   PubMed Web of Science ®Google Scholar
• Farquhar C. Endometriosis. Br. Med. J.334, 249–253 (2007).
   PubMed Web of Science ®Google Scholar
• Laufer MR, Sanfilippo J, Rose G. Adolescent endometriosis: diagnosis and treatment approaches. J. Pediatr. Adolesc. Gynecol.16, S3–S11 (2003).
   PubMedGoogle Scholar
• Koninck PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil. Steril.55, 759–765 (1991).
   PubMedGoogle Scholar
• Ballweg ML. Big picture of endometriosis helps provide guidance on approach to teens: comparative historical data show endo starting younger, is more severe. J. Pediatr. Adolesc. Gynecol.16(Suppl.), S21–S26 (2003).
   Google Scholar
• Guo SW. Recurrence of endometriosis and its control. Hum. Reprod. Update15, 441–461 (2009).
   PubMed Web of Science ®Google Scholar
• Allen C, Hopewell S, Prentice A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst. Rev.2, CD004753 (2009).
   PubMed Web of Science ®Google Scholar
• Davis LJ, Kennedy SS, Moore J, Prentice A. Oral contraceptives for pain associated with endometriosis. Cochrane Database Syst. Rev.3, CD001019 (2007).
   PubMed Web of Science ®Google Scholar
• Winkel CA, Scialli AR. Medical and surgical therapies for pain associated with endometriosis. J. Womens Health Gend. Based Med.10, 137–162 (2001).
   PubMedGoogle Scholar
• Sagsveen M, Farmer JE, Prentice A, Breeze A. Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density. Cochrane Database Syst. Rev.4, CD001297 (2003).
   PubMedGoogle Scholar
• Selak V, Farquhar C, Prentice A, Singla AA. Danazol for pelvic pain associated with endometriosis. Cochrane Database Syst. Rev.4, CD000068 (2007).
   PubMed Web of Science ®Google Scholar
• Vercellini P, Fedele L, Pietropaolo G et al. Progestogens for endometriosis: forward to the past. Hum. Reprod. Update9, 387–396 (2003).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Pharmacological profile of progestins. Maturitas47, 277–283 (2004).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. New progestogens for contraceptive use. Hum. Reprod. Update12, 169–178 (2006).
   PubMed Web of Science ®Google Scholar
• Ylänen K, Laatikainen T, Lähteenmäki P et al. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: clinical response to various doses. Acta Obstet. Gynecol. Scand.82, 167–172 (2003).
   PubMed Web of Science ®Google Scholar
• Federle I, Bianchi S, Zanconato G et al. Comparison of use of levonorgestrel releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil. Steril.75, 485–488 (2001).
   PubMedGoogle Scholar
• Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum. Reprod.19, 179–184 (2004).
   PubMed Web of Science ®Google Scholar
• Oettel M, Carol W, Elger W et al. A 19-norprogestin without 17α-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today31, 517–536 (1995).
   Google Scholar
• Sasagawa S, Shimizu Y, Kami H et al. Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. Steroids73, 222–231 (2008).
   PubMed Web of Science ®Google Scholar
• Köhler G, Faustmann TA, Gerlinger C et al. A dose-ranging study to determine the efficacy and safety of dienogest 1, 2, and 4 mg daily in endometriosis. Int. J. Gynaecol. Obstet.108, 21–25 (2010).
   PubMed Web of Science ®Google Scholar
• Momoeda M, Taketani Y. Randomized, double-blind, multicentre, parallel-group, dose–response study of dienogest in patients with endometriosis. Jpn. Pharmacol. Ther.35(7), 769–783 (2007).
   Google Scholar
• Mueck AO, Seeger H. The pharmacology of dienogest. Gynaecol. Forum14(2), 3–4 (2009).
   Google Scholar
• Mueck AO, Seeger H, Bühling KJ. Why use of dienogest for the first contraceptive pill with estradiol. Gynecol. Endocrinol.26, 109–113 (2010)
   PubMed Web of Science ®Google Scholar
• Römer T. Endometrial effects of estradiol–dienogest combinations. Gynaecol. Forum14(2), 3–4 (2009).
   Google Scholar
• Lippert TH, Mueck AO. The clinical importance of dienogest. In: Dienogest – Preclinical and Clinical Features of a New Progestogen. Teichmann AT (Ed.). Walter de Gruyter, Berlin, Germany, 261–274 (1995).
   Google Scholar
• Telimaa S, Puolakka J, Rönnberg L et al. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol. Endocrinol.1, 13–23 (1987).
   PubMedGoogle Scholar
• Muneyyirci-Delale O, Karacan M. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int. J. Fertil. Womens Med.43, 24–27 (1998).
   PubMedGoogle Scholar
• Mueck AO. What makes dienogest a unique progestogen for the treatment of endometriosis? Gynaecol. Forum15(2), 18–23 (2010).
   Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric8(Suppl. 1), 32 (2005).
   Google Scholar
• Herkert O, Kuhl H, Sandow J et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression. Role of the glucocorticoid receptor. Circulation104, 2826–2831 (2001).
   PubMed Web of Science ®Google Scholar
• Köhler G, Göretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet. Gynecol. Scand.68, 633–635 (1989).
   PubMed Web of Science ®Google Scholar
• Nikschick S, Köhler G, Männchen E. Carbohydrate metabolism during treatment of endometriosis with the progestin dienogest. Exp. Clin. Endocrinol.94, 211–214 (1989).
   PubMedGoogle Scholar
• Seitz C, Gerlinger C, Faustmann T, Strowitzki T. Safety of dienogest in the long-term treatment of endometriosis: a one-year, open-label, follow-up study. Fertil. Steril.92 (2009) (Abstract S107). Presented at: 65th Annual Meeting, American Society for Reproductive Medicine. Atlanta, GA, USA (2009).
   Google Scholar
• Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum. Reprod.25, 633–641 (2010).
   PubMed Web of Science ®Google Scholar
• Okada H, Nakajima T, Yoshimura T et al. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol. Hum. Reprod.7, 341–347 (2001).
   PubMed Web of Science ®Google Scholar
• Katsuki Y, Takano Y, Futamura Y et al. Effects of dienogest, a synthetic steroid, on experimental endometriosis in rats. Eur. J. Endocrinol.138, 216–226 (1998).
   PubMed Web of Science ®Google Scholar
• Fu L, Osuga Y, Morimoto C et al. Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stromal cells. Fertil. Steril.89, 1344–1347 (2008).
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Takeuchi T, Mita S et al. Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression. Mol. Hum. Reprod.15, 693–701 (2009).
   PubMed Web of Science ®Google Scholar
• Horie S, Harada T, Mitsunari M et al. Progesterone and progestational compounds attenuate tumor necrosis factor α-induced interleukin-8 production via nuclear factor kB inactivation in endometriotic stromal cells. Fertil. Steril.83, 1530–1535 (2005).
   PubMed Web of Science ®Google Scholar
• Tatsumi H, Kitawaki J, Tanaka K et al. Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other progestins. Maturitas42, 287–294 (2002).
   PubMed Web of Science ®Google Scholar
• Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cell-induced angiogenesis. Eur. J. Pharmacol.386, 33–44 (1999).
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Wallwiener D. Medroxyprogesterone acetate vs. norethisterone: effect on estradiol induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures. Menopause9, 273–281 (2002).
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Lippert TH. Effect of dienogest on the calcium-influx in human cell cultures. In: Dienogest – Preclinical and Clinical Features of a New Progestogen. Teichmann AT (Ed.). Walter de Gruyter, Berlin, Germany, 135–139 (1995).
   Google Scholar
• Mueck AO, Seeger H, Lüdtke R et al. Effect on biochemical vasoactive markers during postmenopausal hormone replacement therapy: estradiol versus estradiol/dienogest. Maturitas38, 305–313 (2001).
   PubMed Web of Science ®Google Scholar
• Moore C, Carol W, Gräser T et al. Influence of dienogest on ovulation in young fertile women. Clin. Drug Invest.18, 271–278 (1999).
   Web of Science ®Google Scholar
• Schleussner E, Michels E, Bethge W, Klinger G. Die Wirkung von Dienogest auf die hypothalamisch-hypophysäre Achse: Ergebnisse einer Pilotstudie. In: Dienogest – Preclinical and Clinical Features of a New Progestogen. Teichmann AT (Ed.). Walter de Gruyter, Berlin, Germany, 171–179 (1995).
   Google Scholar
• Sasagawa S, Shimizu Y, Nagaoka T et al. Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys. Endocrinol. Invest.31, 636–641 (2008).
   PubMed Web of Science ®Google Scholar
• Oettel M, Breitbarth H, Elger W et al. The pharmacological profile of dienogest. Eur. J. Contracept. Reprod. Health Care4(Suppl. 1), 2–13 (1999).
   Google Scholar
• Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Women’s Health6(1), 27–35 (2010).
   PubMedGoogle Scholar
• Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur. J. Obstet. Gynecol. Reprod. Biol.151, 193–198 (2010).
   PubMed Web of Science ®Google Scholar
• American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil. Steril.67, 817–821 (1997).
   PubMed Web of Science ®Google Scholar
• Cosson M, Querleu D, Donnez J et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, randomized, multicenter, randomized study. Fertil. Steril.77, 684–692 (2002).
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis – a randomized, double-blind, multicenter, controlled trial. Fertil. Steril.91, 675–681 (2009).
   PubMed Web of Science ®Google Scholar
• Momoeda M, Harada T, Terakawa N et al. Long-term use of dienogest for the treatment of endometriosis. J. Obstet. Gynaecol. Res.35, 1069–1076 (2009).
   PubMed Web of Science ®Google Scholar
• Schindler A, Christensen B, Henkel A et al. High-dose pilot study with the novel progestogen dienogest in patients with endometriosis. Gynecol. Endocrinol.22, 9–17 (2006).
   PubMed Web of Science ®Google Scholar
• Schindler AE, Henkel A, Moore C, Oettel M. Effect and safety of high-dose dienogest (20 mg/day) in the treatment of women with endometriosis. Arch. Gynecol. Obstet.282, 507–514 (2010)
   PubMed Web of Science ®Google Scholar